Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis

Alberto Ortiz; Ziad A. Massy; Danilo Fliser; Bengt Lindholm; Andrzej Wiecek; Alberto Martinez-Castelao; Adrian Covic; David Goldsmith; Gueltekin Suleymanlar; Gerard M. London; Carmine Zoccali

doi:10.1038/nrneph.2011.170

Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis

Alberto Ortiz, Ziad A. Massy, Danilo Fliser, Bengt Lindholm, Andrzej Wiecek, Alberto Martinez-Castelao, Adrian Covic, David Goldsmith, Gueltekin Suleymanlar, Gerard M. London, Carmine Zoccali^*

^*Corresponding author for this work

Research output: Contribution to journal › Literature review › peer-review

42 Citations (Scopus)

Abstract

Prognosis, risk stratification and monitoring the effects of treatment are fundamental elements in the decision-making process when implementing prevention strategies for chronic kidney disease. The use of biomarkers is increasingly proposed as a method to refine risk stratification and guide therapy. In this Review, we present basic concepts regarding the validation of biomarkers and highlight difficulties inherent to the identification of useful new biomarkers in patients on hemodialysis. We focus on prognostic biomarkers that have been consistently linked to survival in this group of patients. To date, no biomarker has had sufficient full-scale testing to qualify as a useful addition to standard prognostic factors or to guide the prescription of specific treatments in this population. Furthermore, little information exists on the relative strength of various biomarkers for their prediction of mortality. A multimarker approach might refine prognosis in patients on hemodialysis, but this concept needs to be properly evaluated in large longitudinal studies and clinical trials. The potential of proteomics for the identification and study of new biomarkers in the pathophysiology of cardiovascular disease in patients with end-stage renal disease is also discussed.

Original language	English
Pages (from-to)	141-150
Number of pages	10
Journal	Nature Reviews Nephrology
Volume	8
Issue number	3
DOIs	https://doi.org/10.1038/nrneph.2011.170
Publication status	Published - Mar 2012

Keywords

C-REACTIVE PROTEIN
STAGE RENAL-DISEASE
CHRONIC KIDNEY-DISEASE
LEFT-VENTRICULAR MASS
CARDIAC TROPONIN-I
ASYMMETRIC DIMETHYLARGININE ADMA
SERUM ALKALINE-PHOSPHATASE
LONG-TERM HEMODIALYSIS
ALL-CAUSE MORTALITY
DIALYSIS PATIENTS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrneph.2011.170

Cite this

@article{30c677dc721a4252b94767cfd31c8ef5,

title = "Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis",

abstract = "Prognosis, risk stratification and monitoring the effects of treatment are fundamental elements in the decision-making process when implementing prevention strategies for chronic kidney disease. The use of biomarkers is increasingly proposed as a method to refine risk stratification and guide therapy. In this Review, we present basic concepts regarding the validation of biomarkers and highlight difficulties inherent to the identification of useful new biomarkers in patients on hemodialysis. We focus on prognostic biomarkers that have been consistently linked to survival in this group of patients. To date, no biomarker has had sufficient full-scale testing to qualify as a useful addition to standard prognostic factors or to guide the prescription of specific treatments in this population. Furthermore, little information exists on the relative strength of various biomarkers for their prediction of mortality. A multimarker approach might refine prognosis in patients on hemodialysis, but this concept needs to be properly evaluated in large longitudinal studies and clinical trials. The potential of proteomics for the identification and study of new biomarkers in the pathophysiology of cardiovascular disease in patients with end-stage renal disease is also discussed.",

keywords = "C-REACTIVE PROTEIN, STAGE RENAL-DISEASE, CHRONIC KIDNEY-DISEASE, LEFT-VENTRICULAR MASS, CARDIAC TROPONIN-I, ASYMMETRIC DIMETHYLARGININE ADMA, SERUM ALKALINE-PHOSPHATASE, LONG-TERM HEMODIALYSIS, ALL-CAUSE MORTALITY, DIALYSIS PATIENTS",

author = "Alberto Ortiz and Massy, {Ziad A.} and Danilo Fliser and Bengt Lindholm and Andrzej Wiecek and Alberto Martinez-Castelao and Adrian Covic and David Goldsmith and Gueltekin Suleymanlar and London, {Gerard M.} and Carmine Zoccali",

year = "2012",

month = mar,

doi = "10.1038/nrneph.2011.170",

language = "English",

volume = "8",

pages = "141--150",

journal = "Nature Reviews Nephrology",

issn = "1759-5061",

publisher = "Nature Research",

number = "3",

}

TY - JOUR

T1 - Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis

AU - Ortiz, Alberto

AU - Massy, Ziad A.

AU - Fliser, Danilo

AU - Lindholm, Bengt

AU - Wiecek, Andrzej

AU - Martinez-Castelao, Alberto

AU - Covic, Adrian

AU - Goldsmith, David

AU - Suleymanlar, Gueltekin

AU - London, Gerard M.

AU - Zoccali, Carmine

PY - 2012/3

Y1 - 2012/3

N2 - Prognosis, risk stratification and monitoring the effects of treatment are fundamental elements in the decision-making process when implementing prevention strategies for chronic kidney disease. The use of biomarkers is increasingly proposed as a method to refine risk stratification and guide therapy. In this Review, we present basic concepts regarding the validation of biomarkers and highlight difficulties inherent to the identification of useful new biomarkers in patients on hemodialysis. We focus on prognostic biomarkers that have been consistently linked to survival in this group of patients. To date, no biomarker has had sufficient full-scale testing to qualify as a useful addition to standard prognostic factors or to guide the prescription of specific treatments in this population. Furthermore, little information exists on the relative strength of various biomarkers for their prediction of mortality. A multimarker approach might refine prognosis in patients on hemodialysis, but this concept needs to be properly evaluated in large longitudinal studies and clinical trials. The potential of proteomics for the identification and study of new biomarkers in the pathophysiology of cardiovascular disease in patients with end-stage renal disease is also discussed.

AB - Prognosis, risk stratification and monitoring the effects of treatment are fundamental elements in the decision-making process when implementing prevention strategies for chronic kidney disease. The use of biomarkers is increasingly proposed as a method to refine risk stratification and guide therapy. In this Review, we present basic concepts regarding the validation of biomarkers and highlight difficulties inherent to the identification of useful new biomarkers in patients on hemodialysis. We focus on prognostic biomarkers that have been consistently linked to survival in this group of patients. To date, no biomarker has had sufficient full-scale testing to qualify as a useful addition to standard prognostic factors or to guide the prescription of specific treatments in this population. Furthermore, little information exists on the relative strength of various biomarkers for their prediction of mortality. A multimarker approach might refine prognosis in patients on hemodialysis, but this concept needs to be properly evaluated in large longitudinal studies and clinical trials. The potential of proteomics for the identification and study of new biomarkers in the pathophysiology of cardiovascular disease in patients with end-stage renal disease is also discussed.

KW - C-REACTIVE PROTEIN

KW - STAGE RENAL-DISEASE

KW - CHRONIC KIDNEY-DISEASE

KW - LEFT-VENTRICULAR MASS

KW - CARDIAC TROPONIN-I

KW - ASYMMETRIC DIMETHYLARGININE ADMA

KW - SERUM ALKALINE-PHOSPHATASE

KW - LONG-TERM HEMODIALYSIS

KW - ALL-CAUSE MORTALITY

KW - DIALYSIS PATIENTS

U2 - 10.1038/nrneph.2011.170

DO - 10.1038/nrneph.2011.170

M3 - Literature review

SN - 1759-5061

VL - 8

SP - 141

EP - 150

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

IS - 3

ER -

Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this